You are here


May 26, 2010
Senior State Department Leadership Visit Nigeria Sites

On 26 May, Jack Lew, the U.S. Deputy Secretary of State, and Ambassador Goosby visited a medical centre at the Mogadishu Cantonment in Abuja.

Secretary Lew was impressed with the state of the Reference Laboratory and the Medical Center, which encompass a range of diagnostic and clinical services and provides an effective model for expanding capability to 20 other Nigerian Ministry of...

May 13, 2010
HIV Vaccine Awareness Day 2010

As we mark HIV Vaccine Awareness Day on May 18, I would like to acknowledge the 16,000 volunteers in Thailand, and the hundreds of scientists, health workers, trial staff and members of the U.S. Military HIV Research Program’s team that participated in the RV144 clinical trial.

The prime boost trial in Thailand marked a ‘yes we can’ moment for the field of HIV vaccine development. ...

April 14, 2010
2010 International Military HIV/AIDS Conference

The 2010 International Military HIV/AIDS Conference, co-hosted by the U.S. Department of Defense and the Tanzania People’s Defence Force, was held 12-15 April in Arusha, Tanzania. The theme of this year’s conference was “Building Sustainable Capacity and Leadership to Combat the Pandemic” and brought together representatives from nearly 70 militaries. 

Tanzanian President Jakaya Mrisho...

April 9, 2010
Presidential Commission for the Study of Bioethical Issues

President Barack Obama appointed COL Nelson Michael, the Director of MHRP, to the Commission for the Study of Bioethical Issues.

The Commission will advise the President on bioethical issues that may emerge from advances in biomedicine and related areas of science and technology. President Obama signed an Executive Order creating the new Presidential Commission for the Study of...

March 19, 2010
Early Study Shows MHRP Vaccine Candidate, MVA-CMDR, Safe and Immunogenic

MHRP scientists, working with NIAID, have developed an attenuated viral vector—modified vaccinia Ankara—vaccine candidate, MVA-CMDR (HIV-1 CM235 env/CM240 gag-pol). A Phase I study conducted in the U.S. and Thailand showed the vaccine was safe, well-tolerated and immunogenic. Study results, presented at the 2009 AIDS Vaccine Conference, suggest that MVA-CMDR is an ideal candidate for future...

March 18, 2010
Update on RV144

The Thai Phase III HIV vaccine clinical trial, also known as RV144, was the largest HIV vaccine study ever conducted and involved more than 16,000 volunteers in Thailand. This U.S. Army-sponsored HIV vaccine study showed that an investigational HIV vaccine regimen was safe and modestly effective (31.2% efficacy, mITT analysis) at reducing the rate of HIV infection compared to placebo.


February 24, 2010
Ambassador Goosby Site Visit

Ambassador Goosby visited MHRP’s implementing partner, the Nigeria Ministry of Defense (NMOD) Emergency Plan Implementing committee (EPIC), on February 24, 2010. During his visit, Ambassador Goosby participated in a meeting with COL Ayemoba (representing the chairman of the EPIC from NMOD, Brig. Gen. Tor Umar). The ambassador commended the DOD-NMOD achievements to date, highlighting especially...

February 24, 2010
Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya

A new study published in AIDS Care looked at 222 HIV-positive adult tea plantation workers in western Kenya to assess wellbeing over their first two years on ART. Results showed substantial improvements in physical wellbeing during two years after ART initiation. 

Improvements were largest in the first few months after initiating treatment but were generally sustained over two years....

February 18, 2010
RV144 Update at CROI

COL Nelson Michael, MHRP Director, made a presentation today at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) in San Francisco, California. COL Michael showed some new data on risk factors and breakthrough infections. He also shared some ideas on the way forward for HIV vaccine development. 

MHRP has formed four scientific working groups to help guide...

January 28, 2010
Paper published on Phase I/II Study of a Vaccine Candidate in East Africa

RV 172: A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Boosted by a Multiclade HIV-1 Recombinant ADENOVIRUS-5 Vector Vaccine, VRC-HIVADV014-00-VP in HIV Uninfected Adu


Results from the RV172 study of a vaccine candidate in East Africa conducted by MHRP were published recently in the Journal...